Shattuck Labs (NASDAQ:STTK) Given “Neutral” Rating at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Shattuck Labs (NASDAQ:STTK) in a report published on Friday,Benzinga reports. HC Wainwright also issued estimates for Shattuck Labs’ Q4 2024 earnings at ($0.46) EPS, FY2024 earnings at ($1.54) EPS, FY2025 earnings at ($0.84) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.87) EPS and FY2028 earnings at ($1.03) EPS.

A number of other research analysts have also recently commented on STTK. Citigroup cut Shattuck Labs from a “buy” rating to a “neutral” rating and cut their target price for the company from $8.00 to $2.00 in a research note on Wednesday, October 2nd. Needham & Company LLC reissued a “hold” rating on shares of Shattuck Labs in a research note on Thursday. Finally, Evercore ISI upgraded shares of Shattuck Labs to a “strong-buy” rating in a research note on Wednesday, October 2nd. Four research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $8.67.

Shattuck Labs Trading Down 9.9 %

Shattuck Labs stock opened at $1.24 on Friday. Shattuck Labs has a 12-month low of $1.07 and a 12-month high of $11.76. The firm has a market capitalization of $58.95 million, a PE ratio of -0.81 and a beta of 1.85. The firm has a 50-day moving average price of $2.08 and a 200-day moving average price of $4.19.

Insider Activity

In related news, CEO Taylor Schreiber bought 36,500 shares of the stock in a transaction on Monday, October 7th. The stock was bought at an average price of $1.21 per share, for a total transaction of $44,165.00. Following the completion of the acquisition, the chief executive officer now directly owns 71,002 shares in the company, valued at approximately $85,912.42. This represents a 105.79 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its stake in Shattuck Labs by 0.9% in the third quarter. Geode Capital Management LLC now owns 912,202 shares of the company’s stock valued at $3,184,000 after purchasing an additional 8,133 shares during the last quarter. Barclays PLC boosted its holdings in shares of Shattuck Labs by 299.5% in the 3rd quarter. Barclays PLC now owns 54,311 shares of the company’s stock valued at $189,000 after buying an additional 40,717 shares in the last quarter. EP Wealth Advisors LLC purchased a new position in shares of Shattuck Labs in the 3rd quarter worth approximately $144,000. State Street Corp raised its stake in shares of Shattuck Labs by 7.8% during the 3rd quarter. State Street Corp now owns 766,410 shares of the company’s stock worth $2,675,000 after acquiring an additional 55,579 shares in the last quarter. Finally, Readystate Asset Management LP purchased a new stake in Shattuck Labs during the third quarter valued at approximately $39,000. 58.74% of the stock is owned by institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.